Clinical Characteristics of Tuberculosis Patients with Nephrological Pathology
D. A. Vishnevskiy,
O. N. Zuban,
M. A. Prokopovich,
R. M. Chotchaev,
V. V. Artamonov,
N. V. Andropova https://doi.org/10.58838/2075-1230-2025-103-3-47-51
Abstract
The objective: tto study the structure of kidney disorders in tuberculosis patients.
Subjects and Methods. Data from the unified medical information and analytical system (UMIAS) and medical records of 382 tuberculosis patients with nephrological pathology were retrospcetively analyzed. All those patients underwent in-patient treatment in Extrapulmonary Tuberculosis Department of Clinic no. 2, Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health, from January 1, 2012 to December 31, 2022.
Results. Acute kidney injury induced by anti-tuberculosis drugs was observed in 77/382 (20.2%) patients. Overall, drug-induced toxic nephropathy associated with tuberculosis treatment and comorbid conditions accounted for 111/382 cases (29.1%). Amyloidosis was detected in 42/382 (11.0%) patients, 23/382 (6.0%) underwent deceased-donor kidney transplantation. 61/382 (16.0%) patients had chronic glomerulonephritis. 95 patients received programmed hemodialysis. The main causes of end-stage renal disease in them were chronic glomerulonephritis (30–31.6%), amyloidosis (16–16.8%), and tubulointerstitial nephritis (12–12.6%). Emergency hemodialysis was performed in 43 patients, in 20 (46.5%) patients it was due to tubolointerstitial nephritis caused by anti-tuberculosis drugs, in 7 (16.3%) patients, it was due to some other drugs, and in 14 (32.6%) patients it was due to uric acid nephropathy.
About the Authors
D. A. Vishnevskiy
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
Russian Federation
Russian Federation
Dmitry A. Vishnevskiy, Candidate of Medical Sciences, Nephrologist of Clinic no. 2
10 Stromynka St., Moscow, 107014
O. N. Zuban
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
Russian Federation
Russian Federation
Oleg N. Zuban, Doctor of Medical Sciences, Professor, Deputy Director for Research and Clinical Activities
10 Stromynka St., Moscow, 107014
M. A. Prokopovich
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
Russian Federation
Russian Federation
Maksim A. Prokopovich, Candidate of Medical Sciences, Urologist, Head of Extrapulmonary Tuberculosis Department of Clinic no. 2
10 Stromynka St., Moscow, 107014
R. M. Chotchaev
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
Russian Federation
Russian Federation
Radmir M. Chotchaev, Candidate of Medical Sciences, Urologist, Deputy Head Physician for Medical Activities
10 Stromynka St., Moscow, 107014
V. V. Artamonov
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
Russian Federation
Russian Federation
Vladimir V. Artamonov, Nephrologist of Clinic no. 2
10 Stromynka St., Moscow, 107014
N. V. Andropova
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
Russian Federation
Russian Federation
Natalia V. Andropova, Phthisiologist of Clinic no. 2
10 Stromynka St., Moscow, 107014
References
1. Borisov A.G., Isaev V.V., Zimina V.N. Chronic kidney disease and tuberculosis. Tuberculosis and Lung Diseases, 2013, no. 11, pp. 3-9. (In Russ.)
2. Bushma K.M., Spas V.V., Shapel I.A., Gerasimchuk P.A., Grigoruk A.V. About the nephrotoxicity of aminoglycosides. Novosti Khirurgii, 2009, no. 1, pp. 157-162. (In Russ.)
3. Gordeeva O.M., Karpina N.L. Diagnosis of tuberculosis in patients in end-stage chronic kidney disease. Vrach, 2020, vol. 31, no. 2, pp. 23-29. (In Russ.)
4. Ivanova D.A., Borisov S.E. Profile and risk factors of adverse reactions in new tuberculosis cases receiving treatment. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 6, pp. 22-29. (In Russ.)
5. Ivanyuta O.I., Panaskzh A.B., Suslov E.I. Frequency of amyloidosis of internal organs according to biopsy and autopsy data. Vrachebnoye Delo, 1986, no. 2, pp. 71-74. (In Russ.).
6. Marino P. Svedeniya ob antibakterialnykh sredstvakh. (Russ. Ed.: Paul Marino, Marino`s the ICU Book). Moscow, GEOTARMEDITSINA Publ., 1999, pp. 573-577.
7. Mishin V.Yu. Medikamentoznye oslozhneniya kombinirovannoy khimioterapii tuberkuleza legkikh. [Drug-associated complication of combined chemotherapy of pulmonary tuberculosis]. MIA Publ., Moscow, 2007.
8. Mukhin N.A., Semenkova E.N., Vinogradova O.M. Solovieva A.G. Nonspecific (paratuberculous) reactions in the practice of an internist. Klin. Med. Rekomendatsii, 1989, no. 6, pp. 142-146. (In Russ.).
9. Toktogonova A.A. Frequency and characteristics of adverse reactions to second line anti-tuberculosis drugs in those ill with multiple drug resistant tuberculosis. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 10, pp. 63-67. (In Russ.)
10. Shishkin A.N., Krokhaleva L.L., Fadina Zh.V., Potepun T.B., Azanchevskaya S.V. Specific course of amyloidosis in pulmonary tuberculosis patients. Nephrologiya, 2003, vol. 7, no. 2, pp. 46-49. (In Russ.).
11. Cabrera J., Arroyo V., Ballesta A.M. et.al. Amonoglicoside nephrotoxity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterol., 1982, no. 82, pp. 97-105.
12. Luft F.J. Clinical significance of renal changes engendered by aminoglycosides in man. J. Antimicrob. Chether., 1984, vol. 13, suppl. A, pp. 23-28.
13. Wade J.C., Smith C.R., Petty B.G. et. al. Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus aminoglycoside. Lancet, 1978, vol. 2, no. 8090, pp. 604-606.
Review
For citations:
Vishnevskiy D.A., Zuban O.N., Prokopovich M.A., Chotchaev R.M., Artamonov V.V., Andropova N.V. Clinical Characteristics of Tuberculosis Patients with Nephrological Pathology. Tuberculosis and Lung Diseases. 2025;103(3):47-51. (In Russ.) https://doi.org/10.58838/2075-1230-2025-103-3-47-51
Views:
41
Email this article 